Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1973 Mar;52(3):535–542. doi: 10.1172/JCI107213

Clofibrate-Induced Antidiuresis

Arnold M Moses 1,2, Joan Howanitz 1,2, Marcia Van Gemert 1,2, Myron Miller 1,2
PMCID: PMC302290  PMID: 4685079

Abstract

Normal subjects and patients with antidiuretic hormone (ADH) deficiency were studied to determine the mechanism of the antidiuretic action of clofibrate. Before clofibrate treatment, the patients' ability to concentrate urine with a standardized dehydration procedure correlated with the amount of ADH which was excreted. During clofibrate administration all six patients with ADH deficiency developed an antidiuresis which was like that of ADH, since there was no change in sodium, potassium, total solute, or creatinine excretion. There was a correlation between the patients' ability to concentrate urine during dehydration and the subsequent response to clofibrate, and the excretion of ADH during dehydration correlated with the excretion of ADH on clofibrate therapy. Clofibrate-induced antidiuresis in these patients was partially overcome by ethanol and by water loading. Clofibrate interfered with the ability of patients and subjects to excrete a water load and prevented the water load from inhibiting ADH excretion in the normal subjects. These studies suggested that clofibrate was acting through endogenous ADH and this thesis was supported by the failure of clofibrate to produce an antidiuresis when injected into rats with total ADH deficiency (Brattleboro strain) although an antidiuresis was produced in water-loaded normal rats. When the drug was injected into Brattleboro rats with exogenous ADH, clofibrate either did not alter or it inhibited the action of the ADH. The data demonstrate that clofibrate has a significant ADH-like action. This action appears to be mediated through the release of endogenous ADH.

Full text

PDF
535

Images in this article

537Image
on p.537
539Image
on p.539
540Image
on p.540
540Image
on p.540
540Image
on p.540

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berndt W. O., Miller M., Kettyle W. M., Valtin H. Potentiation of the antidiuretic effect of vasopressin by chlorpropamide. Endocrinology. 1970 May;86(5):1028–1032. doi: 10.1210/endo-86-5-1028. [DOI] [PubMed] [Google Scholar]
  2. Greene H. L., Herman R. H., Zakim D. The effect of clofibrate on rat tissue adenyl cyclase. Proc Soc Exp Biol Med. 1970 Sep;134(4):1035–1038. doi: 10.3181/00379727-134-34938. [DOI] [PubMed] [Google Scholar]
  3. Ingelfinger J. R., Hays R. M. Evidence that chlorpropamide and vasopressin share a common site of action. J Clin Endocrinol Metab. 1969 May;29(5):738–740. doi: 10.1210/jcem-29-5-738. [DOI] [PubMed] [Google Scholar]
  4. KLEEMAN C. R., RUBINI M. E., LAMDIN E., EPSTEIN F. H. Studies on alcohol diuresis. II. The evaluation of ethyl alcohol as an inhibitor of the neurohypophysis. J Clin Invest. 1955 Mar;34(3):448–455. doi: 10.1172/JCI103093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Miller M., Dalakos T., Moses A. M., Fellerman H., Streeten D. H. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med. 1970 Nov;73(5):721–729. doi: 10.7326/0003-4819-73-5-721. [DOI] [PubMed] [Google Scholar]
  6. Miller M., Moses A. M. Mechanism of chlorpropamide action in diabetes insipidus. J Clin Endocrinol Metab. 1970 Apr;30(4):488–496. doi: 10.1210/jcem-30-4-488. [DOI] [PubMed] [Google Scholar]
  7. Miller M., Moses A. M. Potentiation of vasopressin action by chlorpropamide in vivo. Endocrinology. 1970 May;86(5):1024–1027. doi: 10.1210/endo-86-5-1024. [DOI] [PubMed] [Google Scholar]
  8. Miller M., Moses A. M. Radioimmunoassay of urinary antidiuretic hormone in man: response to water load and dehydration in normal subjects. J Clin Endocrinol Metab. 1972 Mar;34(3):537–545. doi: 10.1210/jcem-34-3-537. [DOI] [PubMed] [Google Scholar]
  9. Miller M., Moses A. M. Radioimmunoassay of urinary antidiuretic hormone with application to study of the Brattleboro rat. Endocrinology. 1971 Jun;88(6):1389–1396. doi: 10.1210/endo-88-6-1389. [DOI] [PubMed] [Google Scholar]
  10. Miller M., Moses A. M. Urinary antidiuretic hormone in polyuric disorders and in inappropriate ADH syndrome. Ann Intern Med. 1972 Nov;77(5):715–721. doi: 10.7326/0003-4819-77-5-715. [DOI] [PubMed] [Google Scholar]
  11. Moses A. M., Miller M. Stimulation and inhibition of ACTH release in patients with pituitary disease. J Clin Endocrinol Metab. 1968 Nov;28(11):1581–1588. doi: 10.1210/jcem-28-11-1581. [DOI] [PubMed] [Google Scholar]
  12. Uhlich E., Loeschke K., Eigler J., Halbach R. Clofibrat bei Diabetes insipidus. Klin Wochenschr. 1971 Apr 1;49(7):436–437. doi: 10.1007/BF01485002. [DOI] [PubMed] [Google Scholar]
  13. Valtin H. Hereditary hypothalamic diabetes insipidus in rats (Brattleboro strain). A useful experimental model. Am J Med. 1967 May;42(5):814–827. doi: 10.1016/0002-9343(67)90098-8. [DOI] [PubMed] [Google Scholar]
  14. Webster B., Bain J. Antidiuretic effect and complications of chlorpropamide therapy in diabetes insipidus. J Clin Endocrinol Metab. 1970 Feb;30(2):215–227. doi: 10.1210/jcem-30-2-215. [DOI] [PubMed] [Google Scholar]
  15. Zweig S. M., Ettinger B., Earley L. E. Mechanism of antidiuretic action of chlorpropamide in the mammalian kidney. Am J Physiol. 1971 Sep;221(3):911–915. doi: 10.1152/ajplegacy.1971.221.3.911. [DOI] [PubMed] [Google Scholar]
  16. de Gennes J. L., Bertrand C., Bigorie B., Truffert J. Etudes préliminaires de l'action antidiurétique du clofibrate (ou atromid S) dans le diabète insipide pitressosensible. Ann Endocrinol (Paris) 1970 Mar-Apr;31(2):300–308. [PubMed] [Google Scholar]
  17. de Gennes J. L., Desbois J. C., Marie J. Etude thérapeutique du clofibrate au cours des diabètes insipides pitresso-sensibles de l'enfant. Ann Pediatr (Paris) 1970 Nov 2;17(11):754–759. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES